1. Home
  2. VKTX vs ORA Comparison

VKTX vs ORA Comparison

Compare VKTX & ORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VKTX
  • ORA
  • Stock Information
  • Founded
  • VKTX 2012
  • ORA 1965
  • Country
  • VKTX United States
  • ORA United States
  • Employees
  • VKTX N/A
  • ORA N/A
  • Industry
  • VKTX Biotechnology: Pharmaceutical Preparations
  • ORA Electric Utilities: Central
  • Sector
  • VKTX Health Care
  • ORA Utilities
  • Exchange
  • VKTX Nasdaq
  • ORA Nasdaq
  • Market Cap
  • VKTX 4.7B
  • ORA 4.0B
  • IPO Year
  • VKTX 2015
  • ORA 2004
  • Fundamental
  • Price
  • VKTX $32.87
  • ORA $66.45
  • Analyst Decision
  • VKTX Strong Buy
  • ORA Buy
  • Analyst Count
  • VKTX 12
  • ORA 7
  • Target Price
  • VKTX $106.75
  • ORA $83.57
  • AVG Volume (30 Days)
  • VKTX 3.5M
  • ORA 715.8K
  • Earning Date
  • VKTX 02-05-2025
  • ORA 02-26-2025
  • Dividend Yield
  • VKTX N/A
  • ORA 0.72%
  • EPS Growth
  • VKTX N/A
  • ORA 7.82
  • EPS
  • VKTX N/A
  • ORA 1.96
  • Revenue
  • VKTX N/A
  • ORA $890,253,000.00
  • Revenue This Year
  • VKTX N/A
  • ORA $7.76
  • Revenue Next Year
  • VKTX N/A
  • ORA $10.04
  • P/E Ratio
  • VKTX N/A
  • ORA $34.26
  • Revenue Growth
  • VKTX N/A
  • ORA 12.18
  • 52 Week Low
  • VKTX $20.92
  • ORA $59.41
  • 52 Week High
  • VKTX $99.41
  • ORA $84.30
  • Technical
  • Relative Strength Index (RSI)
  • VKTX 26.61
  • ORA 36.76
  • Support Level
  • VKTX $32.51
  • ORA $65.02
  • Resistance Level
  • VKTX $43.55
  • ORA $68.14
  • Average True Range (ATR)
  • VKTX 2.15
  • ORA 1.43
  • MACD
  • VKTX -0.41
  • ORA 0.24
  • Stochastic Oscillator
  • VKTX 17.78
  • ORA 26.68

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

About ORA Ormat Technologies Inc.

Ormat Technologies Inc is engaged in the geothermal energy power business. The company is engaged in three business segments: Electricity Segment. where the company develops, builds, owns and operates geothermal, solar PV and recovered energy-based power plants in the United States and geothermal power plants in other countries and sell the electricity generated. Product Segment includes designing, manufacturing and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement and construction of geothermal and recovered energy-based power plants. Energy Storage Segment includes owning and operating grid-connected which provide capacity, energy and ancillary services directly to the electric grid.

Share on Social Networks: